🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. Olokizumab 64 mg SC q4w

    International Peace Maternity and Child Health Hospital

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  2. Olokizumab 64mg q4w

    International Peace Maternity and Child Health Hospital

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  3. Olorofim

    Biotech Pharmaceutical Co.,

    Invasive Aspergillosis

    phase 3 small molecule active

    1 trial

  4. Omicron COVID-19 Vaccine (Vero Cell), Inactivated

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 3 mab active

    2 trials

  5. Ondansetron Aurobindo 8 mg Filmtabletten, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Dexametazona Krka 4 mg comprimate, EMEND 125 mg+80 mg hard capsules, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, G

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

    phase 3 small molecule active

    1 trial

  6. Online HDF

    Hospital Authority, Hong Kong

    End Stage Renal Disease

    phase 3 other completed

    1 trial

  7. Oral Budesonide Suspension (OBS)

    Takeda

    Eosinophilic Esophagitis (EoE)

    phase 3 small molecule completed

    2 trials

  8. Oral dexamethasone

    Hospital Authority, Hong Kong

    Bronchiolitis

    phase 3 small molecule completed

    1 trial

  9. Oral immunonutrition

    Hospital Authority, Hong Kong

    Non Small Cell Lung Cancer

    phase 3 other active

    1 trial

  10. Oral sulfate solution (OSS)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bowel Preparation for Colonoscopy

    phase 3 small molecule completed

    1 trial

  11. Orodispersible tablet, BUL03, Jorveza 1 mg orodispersible tablets

    Dr. Falk Pharma GmbH

    eosinophilic esophagitis

    phase 3 small molecule active

    1 trial

  12. Osimertinib

    The First People's Hospital of Lianyungang

    Non-small Cell Carcinoma

    phase 3 small molecule active

    1 trial

  13. Oxaliplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Neoplasms

    phase 3 small molecule active

    1 trial

  14. Oxaliplatin

    The First People's Hospital of Lianyungang

    Rectal Cancer

    phase 3 small molecule active

    1 trial

  15. Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  16. PACLITAXEL , GEMCITABINE , CARBOPLATIN , BNT327, Abraxane 5 mg/ml powder for dispersion for infusion., ERIBULIN , BNT327 Placebo

    BioNTech SE

    First line triple-negative breast cancer (TNBC)

    phase 3 small molecule active

    1 trial

  17. PACLITAXEL , Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion, GEMCITABINE, FOLINIC ACID, FLUOROURACIL

    CERO THERAPEUTICS HOLDINGS, INC.

    Metastatic pancreatic cancer

    phase 3 small molecule active

    1 trial

  18. PACLITAXEL, CISPLATIN, CARBOPLATIN, CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, PEMETREXED, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED

    CERO THERAPEUTICS HOLDINGS, INC.

    Non small cell lung cancer

    phase 3 small molecule active

    1 trial

  19. PACLITAXEL, FLUOROURACIL, DOCETAXEL, EXEMESTANE, DOXORUBICIN, CYCLOPHOSPHAMIDE, EPIRUBICIN, LETROZOLE, TAMOXIFEN, ANASTROZOLE

    Ningbo Cancer Hospital

    patients with node positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX®

    phase 3 small molecule active

    1 trial

  20. PACLITAXEL, GEMCITABINE HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, GEMCITABINE, CISPLATIN, INFLIXIMAB, CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB; either squamous or non-squamous).

    phase 3 small molecule active

    1 trial

  21. PACLITAXEL, LEUPRORELIN, GOSERELIN, TRIPTORELIN, EPIRUBICIN, TRIPTORELIN, EXEMESTANE, RIBOCICLIB, CYCLOPHOSPHAMIDE, LETROZOLE, DOXORUBICIN, GOSERELIN, LEUPRORELIN, ANASTROZOLE, PACLITAXEL ALBUMIN-BOUND, DOCETAXEL

    Ningbo Cancer Hospital

    Patients with HR+ HER2- early breast cancer at intermediate risk of recurrence and eligible for adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  22. PACLITAXEL, MYCOPHENOLATE MOFETIL, Abraxane 5 mg/ml powder for dispersion for infusion., Abraxane 5 mg/ml powder for dispersion for infusion., Rilvegostomig, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN, INFLIXIMAB

    AstraZeneca AB

    Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1

    phase 3 small molecule active

    1 trial

  23. PBSCs

    Hospital Authority, Hong Kong

    Hematological Malignancies

    phase 3 other completed

    1 trial

  24. PCSK9 inhibitors combined with atorvastatin/rosuvastatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources